Lysophosphatidylethanolamine (LPE) is a lyso-type metabolite of phosphatidylethanolamine (a plasma membrane component), and its intracellular Ca(2+) ([Ca(2+)]i) increasing actions may be mediated through G-protein-coupled receptor (GPCR). However, GPCRs for lysophosphatidic acid (LPA), a structurally similar representative lipid mediator, have not been implicated in LPE-mediated activities in SK-OV3 or OVCAR-3 ovarian cancer cells or in receptor over-expression systems. In the present study, LPE-induced [Ca(2+)]i increase was observed in MDA-MB-231 cells but not in other breast cancer cell lines. In addition, LPE- and LPA-induced responses showed homologous and heterologous desensitization. Furthermore, VPC32183 and Ki16425 (antagonists of LPA1 and LPA3) inhibited LPE-induced [Ca(2+)]i increases, and knockdown of LPA1 by transfection with LPA1 siRNA completely inhibited LPE-induced [Ca(2+)]i increases. Furthermore, the involvement of CD97 (an adhesion GPCR) in the action of LPA1 in MDA-MB-231 cells was demonstrated by siRNA transfection. Pertussis toxin (a specific inhibitor of Gi/o proteins), edelfosine (an inhibitor of phospholipase C), or 2-APB (an inhibitor of IP3 receptor) completely inhibited LPE-induced [Ca(2+)]i increases, whereas HA130, an inhibitor of autotaxin/lysophospholipase D, did not. Therefore, LPE is supposed to act on LPA1-CD97/Gi/o proteins/phospholipase C/IP3/Ca(2+) rise in MDA-MB-231 breast cancer cells.
Keywords: (S)-Phosphoric acid mono-{2-octadec-9-enoylamino-3-[4-(pyridin-2-ylmethoxy)-phenyl]-propyl} ester; 2-APB; 2-aminoethoxydiphenylborane; 3-(4-[4-([1-(2-Chlorophenyl)ethoxy]carbonylamino)-3-methyl-5-isoxazolyl]benzylthio) propanoic acid; Breast; G-protein-coupled receptor; GPCR; IP(3); Ki16425; LPA; LPA(1); LPA(2); LPA(3); LPA(4); LPA(5); LPA(6); LPE; LPG; LPS; Lysophosphatidic acid; Lysophosphatidylethanolamine; PTX; Receptor; VPC32183; inositol 1,4,5-trisphosphate; lysophosphatidic acid; lysophosphatidic acid receptor 3 (EDG7); lysophosphatidic acid receptor 5 (GPR92); lysophosphatidic acid receptor 6 (P2Y5); lysophosphatidic acid receptor type 1 (EDG2); lysophosphatidic acid receptor type 2 (EDG4); lysophosphatidic acid receptor type 4 (GPR23); lysophosphatidylethanolamine; lysophosphatidylglycerol; lysophosphatidylserine; pertussis toxin.
© 2013.